Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10070)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
MYCN
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Transferrin receptor protein 1 (TFRC) [Driver; Suppressor; Marker]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Target for Ferroptosis | Marker/Suppressor/Driver | |||
Responsed Disease | Neuroblastoma | ICD-11: 2D50 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model |
SH-EP cells | Neuroblastoma | Homo sapiens | CVCL_0524 |
SK-N-AS cells | Neuroblastoma | Homo sapiens | CVCL_1700 | |
SH-SY5Y cells | Neuroblastoma | Homo sapiens | CVCL_0019 | |
Response regulation | Pediatric neuroblastoma (NB) cells harboring MYCN amplification are prone to undergo ferroptosis conferred by TFRC upregulation, suggesting that GPX4-targeting ferroptosis inducers or TFRC agonists can be potential strategies in treating MYCN-amplified NB. | |||
Neuroblastoma [ICD-11: 2D50]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | N-myc proto-oncogene protein (MYCN) | Protein coding | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model |
SH-EP cells | Neuroblastoma | Homo sapiens | CVCL_0524 |
SK-N-AS cells | Neuroblastoma | Homo sapiens | CVCL_1700 | |
SH-SY5Y cells | Neuroblastoma | Homo sapiens | CVCL_0019 | |
Response regulation | Pediatric neuroblastoma (NB) cells harboring MYCN amplification are prone to undergo ferroptosis conferred by TFRC upregulation, suggesting that GPX4-targeting ferroptosis inducers or TFRC agonists can be potential strategies in treating MYCN-amplified NB. | |||